New York, May 25, 2026, 09:02 EDT
- Adicet Bio (Nasdaq) ended Friday at $8.30, gaining 5.2% ahead of the Memorial Day break.
- The next stock driver looks like it will be the company’s Phase 1 update for prula-cel in lupus nephritis and systemic lupus erythematosus, expected by mid-2026.
- U.S. stock markets are shut Monday for Memorial Day, with trading set to resume on Tuesday.
Adicet Bio shares didn’t move Monday with U.S. markets shut for Memorial Day. Investors are watching the stock after it jumped late last week. Shares ended Friday at $8.30, up 5.2% on the day and gaining 10.7% over the period from May 18 to 22, ahead of key clinical data.
Adicet’s next update is coming up sooner than before. The company says it expects to have Phase 1 data for prulacabtagene leucel, or prula-cel, in at least 20 lupus nephritis and systemic lupus erythematosus patients, with at least six months of follow-up, by mid-2026.
Nasdaq will be closed for Memorial Day on May 25 in 2026, according to the exchange. Normal trading runs from 9:30 a.m. to 4 p.m. Eastern Time. ACET’s next regular session lands on Tuesday.
Adicet traded higher Friday while most biotech names fell. The Nasdaq Biotechnology Total Return Index slipped 0.16% to 6,426.82 on May 22. ACET gained, moving up on thin small-cap volume.
The company wants to show that its “off-the-shelf” cell therapy — donor cells built so they don’t have to create a custom batch for each patient — can actually help in autoimmune disease. CAR T, or chimeric antigen receptor T-cell therapy, uses modified immune cells to go after cells tied to the disease.
Adicet Bio CEO Chen Schor said the next data release is a “key inflection point” for the company, with Phase 1 results expected from at least 20 patients with lupus nephritis and systemic lupus erythematosus. Schor said the trial relies on “a global network of investigators and clinical sites” working on a potential first-in-class gamma delta 1 CAR-T therapy in autoimmune disease. SEC
Schor is set to speak at a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, scheduled for 7:35 a.m. ET. There will be a webcast and replay available for 30 days on Adicet’s investor site.
Adicet posted a first-quarter net loss of $20.2 million, or $1.88 per share, better than the $28.2 million, or $4.96 per share loss in the same period last year. R&D costs dropped to $17.5 million from $22.8 million. G&A expenses also declined, down to $4.1 million from $7.1 million.
Cash is still the key point for the trade. Adicet reported $137.6 million in cash, cash equivalents and short-term investments as of March 31, down from $158.5 million at the end of last year. The company said this cash is enough to fund operations into the second half of 2027.
Competition in the field is rising. Cabaletta Bio is moving forward with rese-cel, a CD19 CAR-T therapy, in systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. Kyverna Therapeutics also works on CAR-T therapies aimed at autoimmune disease.
But the risks are obvious. Adicet’s latest quarterly report says the company relies on prula-cel and warns that its trials might not show enough safety or efficacy, with approvals possibly taking more time. Any soft readout mid-year could bring shares back toward funding concerns, regardless of the quoted cash runway.
ACET comes into the short week trading as a clinical catalyst play. Friday’s bounce gave bulls some relief, but focus is turning to whether the autoimmune readout expected by mid-2026 will be strong enough for a pivotal trial, aiming to back regulatory approval.
